




Newsletter

Newsletter from the European Polyp Surveillance trial

September 2017

Patients included in EPoS as of September 17th, 2017



- Spain, 2378
- Poland, 2040
- Norway, 1959
- The Netherlands, 143
- Sweden, 117
- Denmark, 5
- Portugal, 1



Board Meeting in Tromsø



From the EPoS Board meeting in Tromsø, Norway in November 2016.

Photo: Siv Furholm.

We are proud to present the first European Newsletter of the EPoS trial. Our aim is to share the latest news and updates from all EPoS centres, including the latest inclusion numbers. The Newsletter provides tips and tricks for data management from Frontier Science, and useful information based on experience from the EPoS centres.

The EPoS community is growing bigger, and now entails seven countries. A large number of health professionals in Europe are working every day for

the success of the EPoS trial. Sharing information, experiences, and knowledge will help you at the participating centres to achieve our overarching goal of conducting a high-quality study which will change clinical practice and improve patient care. This month, our special focus is on the new eligibility criteria for patients, please see the new flowchart on page 2. Please share useful information about the EPoS trial by distributing this newsletter to your co-workers and other relevant hospital staff.

EPoS NEWS

New Eligibility Criteria for EPoS Patients

Version 10 of the EPoS protocol is approved in all participating countries (except Portugal). The protocol changes are implemented in the EPoS randomisation system.

Patients eligible for EPoS III according to the new criteria, have already been moved to the correct study by Frontier Science. Please consider advising the patient(s) about the changed surveillance intervals.

Please note; this only applies to patients moved from EPoS I, group 2, with surveillance scheduled after 10 years. After migration to EPoS III, they are now scheduled for an additional surveillance colonoscopy after 5 years.

Eligibility Criteria Flowchart

EPoS I: Low risk adenoma

- **1 or 2 tubular** adenomas
both
- **< 10 mm**
and
- with **low grade dysplasia**


EPoS II: High risk adenoma

- **3 to 10** adenomas
or
- **1 or more** adenoma ≥ 10 mm
or
- **1 or more** adenoma with **high grade dysplasia**
or
- **1 or more** adenoma with **tubulovillous** or **villous** growth pattern

EPoS III: Serrated polyps

(Serrated polyp = SSA/P, TSA or HP)

- **1 or more** serrated polyps ≥ 10 mm (prox. or dist. colon)
- **1 or more** serrated polyps ≥ 5 mm in the prox. colon (proximal to the splenic flexure)
- **SSA/P** with **dysplasia** or **TSA**, all sizes and locations



Missing polyps: EPoS I and EPoS III: **none**. EPoS II: Only 1 polyp < 10 mm may be missing.

Do you need a full-size flowchart in your clinic?

Contact: anita.aalby@medisin.uio.no

EPoS INFO

1 Polyp – 1 Container

We sometimes lose patients for inclusion in EPoS because more than one polyp is put in the same container for histology. Please remember to always use one container per polyp.

Segment – not cm from Sphincter

One of the important variables is colon segment; where the polyp was found. Using cm from the anal sphincter is not a good description of anatomic site, and it leads to unspecific and incorrect data. Therefore, please encourage all endoscopists to include a clear description of which colonic segment each polyp was found in the endoscopy report.

Tips and Tricks from Frontier Science



- Remember to mark the CRF as complete when all data have been entered.
- Fill out the Error Report Form and send to Frontier, if errors are made at randomisation.
- Two or more baseline colonoscopies: The FINAL baseline colonoscopy is registered in the «Baseline Data».
- Previous baseline colonoscopies are registered in «Previous Baseline Colonoscopy», see image below.
- Polyps are registered in the associated colonoscopy CRF. Click «Detected in previous colonoscopy» in the Final baseline colonoscopy if polyps were left in situ previously.

Subject Matrix

15 Show More Select All Event

Study Subject ID	Baseline Data	Previous Baseline Colonoscopy	Unscheduled Colonoscopy	Endpoint/Survival Data	Actions
101037					Apply Filter Clear Filter

- There is a link in Open Clinica which will guide you to support documentation, see image below.



First Paper from the EPoS Trial

We hope the EPoS trial will generate many papers in the future. The first paper has already been published.

Title: Rationale and design of the European Polyp Surveillance (EPoS) trials.

Journal: Endoscopy



Authors: Rodrigo Jover, Michael Bretthauer, Evelien Dekker, Øyvind Holme, Michał F. Kaminski, Magnus Løberg, Ann G. Zauber, Miguel A. Hernán, Iris Lansdorp-Vogelaar, Annike Sunde, Eleanor McFadden, Antoni Castells, Jaroslaw Regula, Enrique Quintero, Maria Pellisé, Carlo Senore, Mette Kalager, Mario Dinis-Ribeiro, Louise Emilsson, David F. Ransohoff, Geir Hoff and Hans-Olov Adami.

Click on the image for access if you are reading this newsletter electronically.


European EPoS Centres




Centres: 14
Country PI: Rodrigo Jover
Sites: Alicante, Barcelona (2 centres), Zaragoza, Vigo, Ourense, Tenerife, Seville, Bilbao, Valladolid, Oviedo, Valencia, Aranda de Duero and Murcia.




Centres: 13
Country PI: Michael Bretthauer
Sites: Oslo (2 centres), Moss, Kalnes, Lørenskog, Tønsberg, Skien, Kragerø, Kristiansand, Trondheim, Stavanger, Tromsø and Bærum.





Centres: 2
Country PI: Michał F. Kaminski
Sites: Warsaw and Cracow.
 Centres starting up in Gdansk and Szczecin.




Centres: 1
Country PI: Hans-Olov Adami
Sites: Karlstad.
 Centre in Stockholm pending.




Centres: 5
Country PI: Evelien Dekker
Sites: Amsterdam (2 centres), Rotterdam, Alkmaar and Deventer.



Centres: 3
Country PI: Rune Erichsen
Sites: Herning, Horsens and Viborg.




Centres: 1
Country PI: Mario Dinis-Ribeiro
Sites: Porto.



EPoS Accruals and Progression

Accruals Europe: 6643 patients



Progression Europe

